

Background, Current Issues

- Artificial Knee Joints made of metal have **High infection risk, Low durability, and Difficulty of revision**
 - A treatment that fits very well for the elderly patient with osteoarthritis (OA). The number of surgeries is on the rise (100,000 in Japan, 800,000 in US)
 - However, the indication of Knee joint replacement surgery is generally limited to elderly patients because of their issues
- Our product (Artificial joint made entirely of cells) solved the issues and **suitable for younger patients and athletes**

Stage of Product, Service or Technology

- Animal POC (Succeeded in Pigs), and Plan to start clinical trial in 2027 in Japan


Product, Service or Technology Overview


- Mass production technology of MSC (Mesenchymal Stem Cell) from iPS cells (iMSC)
- Innovative cartilage product for OA (100% from iPS cells with 3D shaping)
 - Resistant to bacterial infection
 - Same durability as human cartilage
 - Revision is not invasive

Partners We Seek


- Fund raising in 2025(Series A: total 1B JPY)
- Collaborative project partners

Name of contact person: Tomohiro Oiwa
Title: CEO

 <https://arktustx.com/>

 t.oiwa@arktustx.com

Picture of business outlook



Induction technology from iPSC to
MSC
×
3D shaping and maturation